Word: polio
(lookup in dictionary)
(lookup stats)
Dates: during 1950-1959
Sort By: most recent first
(reverse)
Bill McCurdy's team has been picking up points all season by scoring heavily in the short distances and the hurdles. Up to this meet no one has challenged Bob Twitchell and Pete Dew. But Yale has Hank Thresher, sophomore sprinter who has overcome polio to run the 100 in 9.9 and the 220 in 21.6 this season. He is backed by Larry Reno, another sophomore...
...University of Pittsburgh's Dr. Jonas E. Salk, of polio-vaccine fame, reported in the A.M.A. Journal that the technique of preparing killed virus in a mineral-oil suspension (instead of water) works well in influenza vaccines also. His research team, which includes Army medics, said the oil vaccine gives protection against flu for two years (twice as long as the water form) or even longer, and against a larger number of flu-virus strains...
Lois Marshall's triumph came with a rush, at the end of a long, uphill pull. When she was 2½, she came down with polio, and the disease left her with a painful limp. Moreover, in her determination to succeed as a singer, she developed as a youngster such a grimly serious manner that her voice teacher, Toronto's Weldon Kilburn, feared she would never charm an audience. But when she gave her first recital at 15, she dropped her determined air and radiated...
While officials of the National Foundation for Infantile Paralysis sat on the edge of their chairs, Virus Expert Jonas E. Salk of the University of Pittsburgh gave out up-to-date details last week of the vaccine (TIME, Feb. 9) which, it is hoped, can defeat polio. Key points in his review: ¶The virus can be readily cultivated in tissues from monkeys' kidneys. This process gives a higher yield than using monkey testicles (on which earlier experiments were made) and is safer than using brain tissues. ¶After the virus has been killed with formaldehyde, it can still...
...Salk, who is only 38, and the four other members of his research team had answered most of the technical questions about a useful polio vaccine. But many practical problems remained. One, Dr. Salk emphasized, was the care that must be taken to insure that no live virus, capable of causing disease, slips in with the dead virus used in a vaccine. Because this slows down a testing program, said Dr. Salk, he has not had time to think about a mass trial for the vaccine. That may come in 1954. and, if successful, wider use in epidemic areas...